A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008.

Authors: Lior Zvi Braunstein, Melissa Mitchell, Hanna Bandos, William M. Sikov, Atif J. Khan, Peter Y. Chen, Patricia A. Ganz, Reshma Jagsi, Julia R. White, Reena S. Cecchini, Hyejoo Kang, Shannon L. Puhalla, Kelly L. Bolton, Eileen Connolly, Erica Michelle Stringer-Reasor, Kimberly Gergelis, Thomas B. Julian, Eleftherios P. Mamounas, Norman Wolmark

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps1120

Source: Full article


Abstract

TPS1120